With $132M series A, Compass points toward the clinic

Bispecific antibody play Compass Therapeutics LLC (Cambridge, Mass.) raised $49 million Thursday in the final tranche of its series A round, bringing the round's total to $132 million.

OrbiMed Advisers led the round. F-Prime Capital Partners, Cowen Healthcare Investments, Thiel Capital, Biomatics Capital, Ulysses Holdings, Borealis Ventures, Alexandria Real Estate Equities and BioMed Realty Ventures also participated...